Advertisement Fresenius Kabi launches Cisatracurium Besylate Injection in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Fresenius Kabi launches Cisatracurium Besylate Injection in US

German health care firm Fresenius Kabi has launched Cisatracurium Besylate Injection, a new specialty injectable product, in three presentations in the US.

Earlier this year, Cisatracurium Besylate, the generic equivalent of Nimbex, was approved by the US Food and Drug Administration (FDA).

The company specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

Cisatracurium Besylate is an intermediate-onset and intermediate-duration neuromuscular blocker for inpatient and outpatient use as an adjunct to general anesthesia, to facilitate tracheal intubation.

The drug also provides skeletal muscle relaxation during surgery or mechanical ventilation in the intensive care unit.

Fresenius Kabi USA president and CEO John Ducker said: "With the introduction of Cisatracurium, Fresenius Kabi delivers clinicians another choice in neuromuscular blockers while fostering our commitment to provide customers access to one of the most comprehensive anesthesia portfolios in the US."

The drug is available in three presentations: a 10mg per 5mL single use vial, a 20mg per 10mL multiple dose vial and a 200mg per 20mL single use vial.